CA3142295A1 - Benzotriazole derivative - Google Patents
Benzotriazole derivative Download PDFInfo
- Publication number
- CA3142295A1 CA3142295A1 CA3142295A CA3142295A CA3142295A1 CA 3142295 A1 CA3142295 A1 CA 3142295A1 CA 3142295 A CA3142295 A CA 3142295A CA 3142295 A CA3142295 A CA 3142295A CA 3142295 A1 CA3142295 A1 CA 3142295A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- benzo
- triazol
- dimethy1
- oxazepino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019102529 | 2019-05-31 | ||
| JP2019-102529 | 2019-05-31 | ||
| PCT/JP2020/021426 WO2020241853A1 (ja) | 2019-05-31 | 2020-05-29 | ベンゾトリアゾール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3142295A1 true CA3142295A1 (en) | 2020-12-03 |
Family
ID=73553193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3142295A Pending CA3142295A1 (en) | 2019-05-31 | 2020-05-29 | Benzotriazole derivative |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12559504B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3978073B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7524899B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102978107B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114174289B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020283361B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021023927A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3142295A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3047102T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021014680A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020241853A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210030A1 (ar) | 2018-08-20 | 2021-02-16 | Janssen Pharmaceutica Nv | مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2 |
| CN113024399B (zh) * | 2021-03-11 | 2022-09-09 | 华东理工大学 | 药物中间体化合物及其制备方法、应用 |
| KR102994906B1 (ko) * | 2022-01-14 | 2026-07-24 | 주식회사 대웅제약 | Sglt 저해제의 합성에 유용한 중간체의 제조 방법 |
| CA3256688A1 (en) * | 2022-04-28 | 2025-04-22 | Daiichi Sankyo Company, Limited | BENZOTRIAZOLE COMPOUND |
| WO2023210740A1 (ja) * | 2022-04-28 | 2023-11-02 | 第一三共株式会社 | ベンゾチオフェン化合物 |
| EP4696692A1 (en) * | 2023-06-19 | 2026-02-18 | Chugai Seiyaku Kabushiki Kaisha | Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect |
| WO2025192605A1 (ja) * | 2024-03-12 | 2025-09-18 | 株式会社GALTS Pharma | 慢性腎臓病の治療薬、及び慢性腎臓病の治療薬のスクリーニング法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2784244T3 (es) | 2013-12-18 | 2020-09-23 | Glaxosmithkline Ip Dev Ltd | Reguladores de Nrf2 |
| WO2016013657A1 (ja) | 2014-07-25 | 2016-01-28 | 大正製薬株式会社 | ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物 |
| KR20180017038A (ko) | 2015-06-15 | 2018-02-20 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| AU2016280236B2 (en) | 2015-06-15 | 2019-02-07 | Astex Therapeutics Limited | Nrf2 regulators |
| LT3307739T (lt) * | 2015-06-15 | 2021-03-10 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 reguliatoriai |
| US10351530B2 (en) | 2015-10-06 | 2019-07-16 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as NRF2 regulators |
| US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| KR20190088404A (ko) | 2016-12-06 | 2019-07-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 3-(2,3-디히드로-1h-인덴-5-일)프로판산 유도체 및 nrf2 조절제로서의 그의 용도 |
| WO2018109641A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-carboxylic acid pyrroles as nrf2 regulators |
| WO2018109642A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
| ES2901617T3 (es) | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
| EP3555068B1 (en) | 2016-12-14 | 2020-12-02 | GlaxoSmithKline Intellectual Property Development Limited | 3-oxo-1,4-diazepinyle compounds as nrf2 activators |
| JP2020502123A (ja) | 2016-12-14 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2アクチベーターとしてのビスアリール複素環 |
| AU2017376900A1 (en) | 2016-12-15 | 2019-05-23 | Glaxosmithkline Intellectual Property Development Limited | NRF2 compounds |
| JP2020502152A (ja) | 2016-12-15 | 2020-01-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Nrf2アクチベーターとしてのエーテル結合トリアゾール |
| JP2020097526A (ja) | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2019116230A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
| WO2019116231A1 (en) * | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
| US11643407B2 (en) | 2018-05-23 | 2023-05-09 | Glaxosmithkline Intellectual Property Development Limited | Indanes as NRF2 activators |
| JOP20210030A1 (ar) | 2018-08-20 | 2021-02-16 | Janssen Pharmaceutica Nv | مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2 |
| UA127872C2 (uk) | 2018-12-05 | 2024-01-31 | Скохія Фарма, Інк. | Макроциклічна сполука та її застосування |
| KR102932313B1 (ko) | 2019-02-15 | 2026-02-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 활성화제로서 히드록시피리드옥사제핀 |
| WO2021002473A1 (ja) | 2019-07-03 | 2021-01-07 | 千寿製薬株式会社 | Nrf2活性化化合物 |
| AU2021226994A1 (en) | 2020-02-28 | 2022-09-08 | Les Laboratoires Servier | New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them |
-
2020
- 2020-05-29 CN CN202080055155.9A patent/CN114174289B/zh active Active
- 2020-05-29 JP JP2021522912A patent/JP7524899B2/ja active Active
- 2020-05-29 BR BR112021023927A patent/BR112021023927A2/pt unknown
- 2020-05-29 MX MX2021014680A patent/MX2021014680A/es unknown
- 2020-05-29 WO PCT/JP2020/021426 patent/WO2020241853A1/ja not_active Ceased
- 2020-05-29 AU AU2020283361A patent/AU2020283361B2/en active Active
- 2020-05-29 EP EP20815167.0A patent/EP3978073B1/en active Active
- 2020-05-29 KR KR1020217042003A patent/KR102978107B1/ko active Active
- 2020-05-29 CA CA3142295A patent/CA3142295A1/en active Pending
- 2020-05-29 US US17/614,941 patent/US12559504B2/en active Active
- 2020-05-29 ES ES20815167T patent/ES3047102T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020283361B2 (en) | 2025-11-27 |
| CN114174289A (zh) | 2022-03-11 |
| US20220259223A1 (en) | 2022-08-18 |
| US12559504B2 (en) | 2026-02-24 |
| WO2020241853A1 (ja) | 2020-12-03 |
| ES3047102T3 (en) | 2025-12-03 |
| EP3978073A4 (en) | 2023-07-12 |
| MX2021014680A (es) | 2022-04-06 |
| BR112021023927A2 (pt) | 2022-02-08 |
| CN114174289B (zh) | 2025-03-07 |
| KR20220016124A (ko) | 2022-02-08 |
| EP3978073B1 (en) | 2025-10-15 |
| JP7524899B2 (ja) | 2024-07-30 |
| KR102978107B1 (ko) | 2026-06-16 |
| EP3978073A1 (en) | 2022-04-06 |
| JPWO2020241853A1 (cg-RX-API-DMAC7.html) | 2020-12-03 |
| EP3978073C0 (en) | 2025-10-15 |
| AU2020283361A1 (en) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7524899B2 (ja) | ベンゾトリアゾール誘導体 | |
| EP3634404B1 (en) | Pyrazole magl inhibitors | |
| EP4356969B1 (en) | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | |
| KR20190026827A (ko) | 방향족 아세틸렌 또는 방향족 에틸렌계 화합물, 그의 중간체, 제조 방법, 약물 조성물 및 용도 | |
| CA3172478A1 (en) | Bcl-2 inhibitor | |
| CA3110576A1 (en) | Compounds for treating certain leukemias | |
| PH12015500735B1 (en) | Anti-fibrotic pyridinones | |
| TW201311692A (zh) | 三唑並嘧啶類衍生物、其製備方法及其在醫藥上的應用 | |
| EP3675848A1 (en) | Spirocycle compounds and methods of making and using same | |
| CZ285799B6 (cs) | Indolové deriváty, způsob jejich výroby, jejich použití pro výrobu farmaceutických prostředků a farmaceutické prostředky s jejich obsahem | |
| CA2860187A1 (en) | Cyclic amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase and uses thereof | |
| IL269119B2 (en) | Dual inhibitors of magl and faah | |
| KR20220141331A (ko) | P2x3 조정제 | |
| CA3127268A1 (en) | Heterocyclic derivatives | |
| WO2024078392A1 (en) | Phosphoramidate compounds and uses thereof | |
| EP3759113B1 (en) | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| RU2670982C2 (ru) | ПРОИЗВОДНЫЕ α-ЗАМЕЩЕННОГО ГЛИЦИНАМИДА | |
| RU2840112C2 (ru) | Производные бензотриазола | |
| OA21175A (en) | Inhibitors of APOL1 and methods of using same. | |
| WO2026060256A1 (en) | Sting inhibitors and uses thereof | |
| CN122029151A (zh) | 他汀类衍生物及其使用方法 | |
| HK40055239B (en) | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections | |
| HK40042824A (en) | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| HK40042824B (en) | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| WO2010025436A2 (en) | Nitrogen and sulfur-containing heterocycle derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240321 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250409 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250523 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250911 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251224 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251224 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251224 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260317 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260317 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260623 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260623 |